Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics

References

• Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271: 195–204
   PubMed Web of Science ®Google Scholar
• Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001; 20: 591–598
   PubMed Web of Science ®Google Scholar
• Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Coenzyme Q10 in health and disease. Eur J Clin Nutr 1999; 53: 764–770
   PubMed Web of Science ®Google Scholar
• Langsjoen PH, Langsjoen AM. Overview of the use of coenzyme Q10 in cardiovascular disease. Biofactors 1999; 9: 273–284
   PubMed Web of Science ®Google Scholar
• Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Rad Res 2002; 36: 455–460
   PubMed Web of Science ®Google Scholar
• Katayama K, Fujita T. Studies on the lymphatic absorption of 1′,2′-(3H)-coenzyme Q10 in rats. Chem Pharm Bull 1972; 250: 2585–2592
   Google Scholar
• Craft NE, Tucker RT, Chitchumroonchokchai C, Failla M, Bhagavan HN. Assessment of coenzyme Q10 bioavailability using a coupled in vitro digestion/Caco-2 human intestinal cell model. FASEB J 2005; 19: A449
   PubMedGoogle Scholar
• Elmberger PG, Kalen A, Brunk UT, Dallner G. Discharge of newly-synthesized dolichol and ubiquinone with lipoproteins to rat liver perfusate and to the bile. Lipids 1989; 24: 919–930
   PubMed Web of Science ®Google Scholar
• Traber MG, Lne JC, Lagmay NR, Kayden HJ. Studies on the transfer of tocopherol between lipoproteins. Lipids 1992; 27: 657–663
   PubMed Web of Science ®Google Scholar
• Laaksonen R, Riihimaki A, Laitila J, Martensson K, Tikkanen MJ, Himberg JJ. Serum and muscle tissue ubiquinone levels in healthy subjects. J Lab Clin Med 1995; 125: 517–521
   PubMed Web of Science ®Google Scholar
• Aberg F, Appelkvist EL, Dallner G, Ernster L. Distribution and redox state of ubiquinones in rat and human tissues. Arch Biochem Biophys 1992; 295: 230–234
   PubMed Web of Science ®Google Scholar
• Miles MV, Horn PS, Morrison JA, Tang PH, DeGrauw T, Pesce AJ. Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults. Clin Chim Acta 2003; 332: 123–132
   PubMed Web of Science ®Google Scholar
• Zhang Y, Aberg F, Appelkvist E-L, Dallner G, Ernster L. Uptake of dietary coenzyme Q supplement is limited in rats. J Nutr 1995; 125: 446–453
   PubMed Web of Science ®Google Scholar
• Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res 1998; 68: 109–113
   PubMed Web of Science ®Google Scholar
• Miles MV, Horn P, Miles L, Tang P, Steele P, DeGrauw T. Bioequivalence of coenzyme Q10 from over-the-counter supplements. Nutr Res 2002; 22: 919–929
   Web of Science ®Google Scholar
• Zaghloul AA, Gurley B, Khan M, Bhagavan H, Chopra R, Reddy I. Bioavailability assessment of oral coenzyme Q10 formulations in dogs. Drug Dev Ind Pharm 2002; 28: 1195–1200
   PubMed Web of Science ®Google Scholar
• Greenberg S, Frishman WH. Co-enzyme Q10: A new drug for cardiovascular disease. J Clin Pharmacol 1990; 30: 596–608
   PubMed Web of Science ®Google Scholar
• Zhang Y, Turunen M, Appelkvist E-L. Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of α-tocopherol into rat organs and cells. J Nutr 1996; 126: 2089–2097
   PubMedGoogle Scholar
• Lonnrot K, Metsa-Katela T, Molnar G, Ahonen J-P, Latvala M, Peltola J, Pietila T, Alho H. The effect of acsorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity. Free Rad Biol Med 1996; 21: 211–217
   PubMed Web of Science ®Google Scholar
• Tomasetti M, Littarru GP, Stocker R, Alleva R. Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes. Free Radic Biol Med 1999; 27: 1027–1032
   PubMed Web of Science ®Google Scholar
• Alessandri MG, Scalori V, Giovannini L, Mian M, Bertelli AAE. Plasma and tissue concentrations of coenzyme Q10 in the rat after intravenous administration by a microsphere delivery system or in a new type of solution. Int J Tiss React 1988; 10: 99–102
   PubMedGoogle Scholar
• Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 1998; 95: 8892–8897
   PubMed Web of Science ®Google Scholar
• Kwong LK, Kamzalov S, Rebrin I, Bayne A-CV, Jana CK, Morris P, Forster MJ, Sohal RS. Effects of coenzyme Q10 administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic Biol Med 2002; 33: 627–638
   PubMed Web of Science ®Google Scholar
• Kamzalov S, Sumien N, Forster MJ, Sohal RS. Coenzyme Q intake elevates the mitochondrial and tissue levels of coenzyme Q and α-tocopherol in young mice. J Nutr 2003; 133: 3175–3180
   PubMed Web of Science ®Google Scholar
• Fujita T, Tanayama S, Shirakawa Y. Metabolic fate of ubiquinone-7. I. Absorption, excretion and tissue distribution in rats. J Biochem 1971; 69: 53–61
   PubMed Web of Science ®Google Scholar
• Kishi H, Kanamori N, Nishii S, Hiraoka E, Okamoto T, Kishi T. Metabolism of exogenous coenzyme Q10 in vivo and the bioavailability of coenzyme Q10 preparations in Japan. Biomedical and clinical aspects of coenzyme Q, K Folkers, Y Yamamura. Elsevier, Amsterdam 1964; 131–142
   Google Scholar
• Lonnrot K, Holm P, Lagerstedt A, Huhtala H, Alho H. The effects of lifelong ubiquinone Q10 supplementation on the Q9 and Q10 tissue concentrations and life span of male rats and mice. Biochem Mol Biol Intern 1998; 44: 727–737
   PubMedGoogle Scholar
• Nakamura T, Ohno T, Hamamura K, Sato T. Metabolism of coenzyme Q10: Biliary and urinary excretion study in Guinea pigs. Biofactors 1999; 9: 111–119
   PubMed Web of Science ®Google Scholar
• Bentinger M, Dallner G, Chojnacki T, Swiezewska E. Distribution and breakdown of labeled coenzyme Q10 in rat. Free Radic Biol Med 2003; 34: 563–575
   PubMed Web of Science ®Google Scholar
• Lang JK, Packer L. Quantitative determination of vitamin E and oxidized and reduced coenzyme Q by HPLC with in-line ultraviolet and electrochemical detection. J Chromatogr 1987; 385: 109–117
   PubMedGoogle Scholar
• Edlund PO. Determination of coenzyme Q10, α-tocopherol and cholesterol in biological samples by coupled-column liquid chromatography with coulometric and ultraviolet detection. J Chromatogr 1988; 425: 87–97
   PubMed Web of Science ®Google Scholar
• Grossi G, Bargossi AM, Fiorella PL, Piazzi S. Improved high-performance liquid chromatographic method for the determination of coenzyme Q10 in plasma. J Chromatogr 1992; 593: 217–226
   PubMed Web of Science ®Google Scholar
• Finckh B, Kontush A, Commentz J, Hubner C, Burdelski M, Kohlschutter A. Monitoring of ubiquinol-10, ubiquinone-10, carotenoids, and tocopherols in neonatal plasma microsamples using high-performance liquid chromatography with coulometric electrochemical detection. Anal Biochem 1995; 232: 210–216
   PubMedGoogle Scholar
• Lagendijk J, Ubbink JB, Delport R, Hayward WJ, Human JA. Measurement of the ratio between the reduced and oxidized forms of CoQ10 in human plasma as a possible marker of oxidative stress. J Lipid Res 1996; 37: 67–75
   PubMed Web of Science ®Google Scholar
• Kaikkonen J, Nyyssonen K, Tuomainen T-P, Ristonmaa U, Salonen JT. Determinants of plasma coenzyme Q10 in humans. FEBS Lett 1999; 443: 163–166
   PubMed Web of Science ®Google Scholar
• Tang PH, Miles MV, DeGrauw A, Hershey A, Pesce A. HPLC analysis of reduced and oxidized coenzyme Q(10) in human plasma. Clin Chem 2001; 47: 256–265
   PubMed Web of Science ®Google Scholar
• Duncan AJ, Heales SJR, Mills K, Eaton S, Land JM, Hargreaves IP. Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard. Clin Chem 2005; 51: 2380–2382
   PubMed Web of Science ®Google Scholar
• Steele PE, Tang PH, DGrauw AJ, Miles MV. Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases. Am J Clin Pathol 2004; 121: S113–S120
   PubMedGoogle Scholar
• Kaikkonen J, Tuomainen E-P, Nyyssonen K, Salonen JT. Coenzyme Q10: Absorption, antioxidative properties, determinants, and plasma levels. Free Radic Res 2002; 36: 389–397
   PubMed Web of Science ®Google Scholar
• Hughes K, Lee BL, Feng X, Lee J, Ong CN. Coenzyme Q10 and differences in coronary heart disease risk in Asian Indians and Chinese. Free Radic Biol Med 2002; 32: 132–138
   PubMedGoogle Scholar
• Niklowitz P, Menke T, Andler W, Okun JG. Simultaneous analysis of coenzyme Q10 in plasma, erythrocytes and platelets: Comparison of the antioxidant level in blood cells and their environment in healthy children and after oral supplementation in adults. Clin Chim Acta 2004; 342: 219–226
   PubMed Web of Science ®Google Scholar
• Becker K, Boetticher D, Leichsenring M. Ubiquinone-10 plasma concentrations in healthy European children. Redox Rep 1995; 1: 97–98
   PubMed Web of Science ®Google Scholar
• Miles MV, Horn PS, Tang PH, Morrison JA, Miles L, Degrauw T. Age-related changes in plasma coenzyme Q10 concentrations and redox state in apparently healthy children and adults. Clin Chim Acta 2004; 347: 139–144
   PubMed Web of Science ®Google Scholar
• Lyon W, Van den Brink O, Pepe S, Wowk M, Marasco S, Rosenfeld FL. Similar therapeutic serum levels attained with emulsified and oil-based preparations of coenzyme Q10. Asia Pac J Clin Nutr 2001; 10: 212–215
   PubMed Web of Science ®Google Scholar
• Kaikkonen J, Nyyssonen K, Porkkala-Sarataho E, Poulsen HE, Metsa-Katela T, Hayn M, Salonen R, Salonen JT. Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: Absorption and antioxidative properties of oil and granule-based preparations. Free Radic Biol Med 1997; 22: 1195–1202
   PubMed Web of Science ®Google Scholar
• Zita C, Overvad K, Mortensen SA, Sindberg CD, Moesgaard S, Hunter DA. Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomized controlled study. Biofactors 2003; 18: 185–189
   PubMed Web of Science ®Google Scholar
• Folkers K, Moesgaard S, Morita M. A one year bioavailability study of coenzyme Q10 with 3 months withdrawal period. Mol Aspects Med 1994; 15: s281–s285
   PubMedGoogle Scholar
• Weber C, Jakobsen TS, Mortensen SA, Paulsen G, Holmer G. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. Int J Vitam Nutr Res 1994; 64: 311–315
   PubMed Web of Science ®Google Scholar
• Lu W-L, Zhang Q, Lee H-S, Zhou T-Y, Sun H-D, Zhang D-W, Zheng L, Lee M, Wong S-M. Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets. Biol Pharm Bull 2003; 26: 52–55
   PubMed Web of Science ®Google Scholar
• Thelin A, Schedin S, Dallner G. Half-life of ubiquinone-9 in rat tissues. FEBS Lett 1992; 313: 118–120
   PubMedGoogle Scholar
• Tomono Y, Hasegawa J, Seki T, Motegi K, Morishita N. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int J Clin Phramacol Ther Toxicol 1986; 24: 536–541
   PubMedGoogle Scholar
• Lucker PW, Wetzelsberger N, Hennings G, Rehn D. Pharmacokinetics of coenzyme ubidecarenone in healthy volunteers. Biomedical and clinical aspects of coenzyme Q, K Folkers, Y Yamamura. Elsevier Science Publishers, Amsterdam 1984; 4: 141–151
   Google Scholar
• Weiss M, Mortensen SA, Rassing MR, Moller-Sonnergaard J, Poulsen G, Rasmussen SN. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 1994; 15: s273–s280
   PubMedGoogle Scholar
• Yuzuriha T, Takada M, Katayama K. Transport of [14C] coenzyme Q10 from the liver to other tissues after intravenous administration to guinea pigs. Biochim Biophys Acta 1983; 759: 286–291
   PubMed Web of Science ®Google Scholar
• Gold DR, Cohen BH. Treatment of mitochondrial cytopathies. Semin Neurol 2001; 21: 309–325
   PubMedGoogle Scholar
• Schon EA, DiMauro S. Medicinal and genetic approaches to the treatment of mitochondrial disease. Curr Med Chem 2003; 10: 2523–2533
   PubMed Web of Science ®Google Scholar
• Shults CW. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003; 10: 1917–1921
   PubMed Web of Science ®Google Scholar
• Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: A controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56: 1137–1142
   PubMed Web of Science ®Google Scholar
• Bliznakov EG, Chopra RK, Bhagavan HN. Coenzyme Q10 and neoplasia: Overview of experimental and clinical evidence. Phytopharmaceuticals in cancer chemoprevention, D Bagchi, HG Preuss. CRC Press, Boca Raton 2004; 599–622
   Google Scholar
• Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: An update. Curr Opin Clin Nutr Metab Care 2005; 8: 641–646
   PubMed Web of Science ®Google Scholar
• Langsjoen PH, Langsjoen AM. Coenzyme Q10 in cardiovascular disease with emphasis on heartfailure and myocardial ischemia. Asia Pac Heart J 1998; 7: 160–168
   Google Scholar
• Kieburtz K. A randomized placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Nerurology 2001; 57: 397–404, (The Huntington Study Group).
   PubMedGoogle Scholar
• Shultz CW, Oakes D, Kieburtz K, Beal FL, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M. Effects of coenzyme Q10 in early Parkinson disease. Arch Neurol 2002; 59: 1541–1550, and the Parkinson Study Group.
   PubMedGoogle Scholar
• Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 2005; 4: 110–130
   PubMedGoogle Scholar
• Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of coenzyme Q10 biosynthesis by lipid-lowering HMG–CoA reductase inhibitors (statins): A critical review. Adv Therap 1998; 15: 218–228
   Web of Science ®Google Scholar
• Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors 2003; 18: 101–111
   PubMed Web of Science ®Google Scholar
• Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10-enzymes by clinically used anti-hypertensive drugs. Res Commun Chem Pathol Pharmacol 1975; 12: 533–540
   PubMedGoogle Scholar
• Kishi T, Kishi H, Watanabe T, Folkers K. Bioenergetics in clinical medicine. XI. Studies on coenzyme Q and diabetes mellitus. J Med 1976; 7: 307–321
   PubMedGoogle Scholar
• Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000; 57: 1221–1227
   PubMed Web of Science ®Google Scholar
• Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990; 65: 421–423
   Google Scholar
• Jones K, Hughes K, Mischley L, McKenna D. Coenzyme Q10: Efficacy, safety, and use. Int J Integr Med 2002; 4: 28–43
   Google Scholar
• Williams KD, Maneke JD, Abdelhameed M, Hall RL, Palmer TE, Kitano M, Hidaka T. 52-Week oral gavage chronic toxicity study with ubiquinone in rats with a 4-week recovery. J Agric Food Chem 1999; 47: 3756–3763
   PubMedGoogle Scholar
• Shults CW, Beal MF, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 2004; 188: 491–494
   PubMed Web of Science ®Google Scholar
• Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiburg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M. Tolerance of high-dose (3000 mg/day) Coenzyme Q10 in ALS. Neurology 2005; 65: 1834–1836
   PubMed Web of Science ®Google Scholar